| Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses | Frank Vinluan | 05/01/20 | Boston |
| X4 Completes Reverse Merger with Arsanis, Looks Ahead to Phase 3 Test | Frank Vinluan | 03/13/19 | Boston |
| X4 Pharma Heads to Nasdaq Via Reverse Merger with Arsanis | Ben Fidler | 11/27/18 | Boston |
| With CRISPR’s Help, KSQ Touts 13 Cancer Drugs and Bags Another $80M | Ben Fidler | 09/28/18 | Boston |
| LogicBio Jumps on the Gene Therapy 2.0 Wave and Lines Up an IPO | Frank Vinluan | 09/26/18 | Boston |
| Bio Roundup: Funding Frenzy, Opioid Summit, Celgene Woes & More | Ben Fidler | 03/02/18 | National |
| Avrobio Raises $60M for Fabry Disease Gene Therapy, Rest of Pipeline | Frank Vinluan | 02/01/18 | Boston |
| After Humanitarian Honor, Flagship’s Afeyan States Case for Immigration | Frank Vinluan | 12/06/17 | Boston |
| Ed Kaye on Sarepta’s Duchenne Quest, Rising to CEO & His New Startup | Ben Fidler | 11/20/17 | Boston |
| X4 Pharma Pulls In $27M for Immune Drug in Cancer, Rare Diseases | Frank Vinluan | 11/16/17 | Boston |
| Sanofi Pulls Back from Voyager Gene Therapy Pact in Parkinson’s | Frank Vinluan | 10/31/17 | Boston |
| The Winners of the Xconomy Lifetime Achievement Award Are… | Corie Lok | 09/12/17 | Boston |
| Startup Builders, IPO Closers & More: Meet Xconomy’s CEO Award Finalists | Ben Fidler | 08/10/17 | Boston |
| Bio Leaders Mourn Passing of Genzyme Exec, Orphan Drug Innovator Termeer | Ben Fidler | 05/14/17 | Boston |
| Stalled or Rising Momentum? New York Wrestles With Its Biotech Future | Ben Fidler | 05/10/17 | New York |
| Bio Roundup: Gottlieb Talks Vax, Acorda’s Axe, Adams, 23andMe & More | Alex Lash | 04/07/17 | National |
| Boston Startup Exit Data Show Region’s Shift From Tech to Healthcare | Jeff Bauter Engel | 04/04/17 | Boston |
| At Arrakis, Gilman Teams With Biogen Vets to Target RNA With Pills | Ben Fidler | 02/27/17 | Boston |
| Voyager’s Gene Therapy for Parkinson’s Shows Promise in Small Study | Ben Fidler | 12/07/16 | Boston |
| Amicus Shares Fall On Another Bump in Rough Road To U.S. Fabry Nod | Ben Fidler | 11/28/16 | New York |
| Should We Rewrite the Human Genome? | Alex Harding | 11/28/16 | Boston |
| Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More | Ben Fidler | 09/30/16 | National |
| Amylyx Nabs $5M to Take Aim at Nerve Cell Death in ALS Patients | David Holley | 08/22/16 | Boston |
| Audentes Prices $75M IPO As Gene Therapy Eyes First U.S. Approval | Ben Fidler | 07/20/16 | San Francisco |
| Alnylam Advances RNAi Drug Results After Two Years of Treatment | David Holley | 07/01/16 | Boston |
| Vedanta Nabs $50M To Expand Microbiome Into Immune-Boosting Therapies | Ben Fidler | 06/06/16 | Boston |
| Near-Term FDA Nod Unlikely For Duchenne Drug After Negative Vote | Ben Fidler | 04/25/16 | Boston |
| For San Antonio’s Consideration: A Biotech Incubator and Accelerator | David Holley | 04/08/16 | Texas |
| At Long Last, First Drug Approval in Sight for Amicus | Ben Fidler | 04/01/16 | New York |
| East Coast Bio Roundup: PCSK9 Battle, NYU Startups, Blueprint & More | Ben Fidler | 03/17/16 | Boston |
